Why this newly public biotech could become a force in obesity treatments

Published on:

February 25, 2025

[ad_1]

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

[ad_2]

Source link

Leave a Reply Cancel reply

Please enter your comment!

Please enter your name here

You have entered an incorrect email address!

Please enter your email address here

WorldDesk https://news.projectliberte.io

Subscribe now

To access premium content

Immortals and Fetch.ai Form Landmark Crypto Partnership

The Metaverse Creation, Ronin Wallet is Live & More News

Ubisoft To Develop Blockchain Games, Enjin’s $100 Million Fund

All About Play to Earn With Crypto Games (P2E)

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead

Why this newly public biotech could become a force in obesity treatments

Related

If Spirit ends up shutting down, these airlines stand to benefit

AI Mining Pivot, ETH Bets, Stablecoin Pause

New homeowners pay 3 times more property tax than their neighbors in some places. Here’s what they can do about it.

Bitcoin ETFs Post Strong April Inflows as Ether Turns Positive

Brazil Central Bank Bars Virtual Assets From eFX Payments

The S&P 500’s newest member is this under-the-radar software stock

Bitcoin Price Action Favors Bears But Profit Taking Overwhelms Each Rally

Leave a Reply Cancel reply